Revenue ($USD): $1,168,660,000
R&D spend: $50,131,000.00
Employees: 3,034
Fiscal year end: 04/01/23
CEO: Christopher Simon
News this year includedFDA clearance of advancements to its NexSys PCS plasma collection system.
Haemonetics alsoinvested €30 millionin Galway, Ireland-based Vivasure and its portfolio of fully absorbable, patch-based, large-bore percutaneous vessel closure devices. The agreement includes an option for Haemonetics to acquire Vivasure.–CN and SW